MDR_Button Contact_Button News_Button  

CBA Pharma Moving Forward

As of the second quarter of 2012, the Board of Directors of CBA Pharma, Inc. decided it was in the best interest of the Company to seek one or more large pharmaceutical partners to complete the NDA process with the FDA and commercialize CBT-1® in the United States and/or international markets.

 

 
 
Column Header 1 Column Header 2 Column Header 3
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.

 

© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions